41 completed. 41 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 41 | Completed 41 |
| Phase 2 | 19 | Completed 19 |
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor MGTA-145, plerixafor, Placebo - Healthy Volunteers | Phase 1 | Completed | Ensoma | 107 | 2019-04-22 | 2024-01-11 |
| A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease Plerixafor, Busulfan, BIVV003 - Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 7 | 2019-03-06 | 2025-09-12 |
| Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) Plerixafor, Alemtuzumab, Anakinra - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Completed | University of Alberta | 22 | 2017-08-15 | 2024-07-19 |
| Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Plerixafor - Sickle Cell Disease | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-07-25 | 2023-09-21 |
| Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor G-CSF, Plerixafor - Fanconi Anemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 4 | 2017-02-10 | 2025-09-11 |
| Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Plerixafor - Sickle Cell Disease Without Crisis | Phase 1 | Completed | Alessandra Biffi | 6 | 2017-01-01 | 2018-01-25 |
| Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients Plerixafor - Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 3 | 2016-01-15 | 2025-09-05 |
| Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs), Genetically Engineered Hematopoietic Stem/Progenitor Cells, Laboratory Biomarker Analysis - Fanconi Anemia | Phase 1 / Phase 2 | Completed | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 9 | 2016-01-07 | 2024-03-21 |
| Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Selinexor, Cladribine, G-CSF - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 40 | 2015-06-16 | 2020-03-13 |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Plerixafor - Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma | Phase 1 | Completed | CCTU- Cancer Theme | 26 | 2015-06-01 | 2019-07-23 |
| Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma radiation therapy, temozolomide, plerixafor - Adult Ependymoblastoma, Adult Giant Cell Glioblastoma | Phase 1 / Phase 2 | Completed | Lawrence Recht | 30 | 2014-11-01 | 2018-10-23 |
| Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease Plerixafor - Sickle Cell Disease | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2014-09-17 | 2025-03-30 |
| A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone plerixafor - Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma | Phase 1 / Phase 2 | Completed | Genzyme, a Sanofi Company | 46 | 2014-03-03 | 2017-05-16 |
| Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation Plerixafor mobilization of autologous CD117 stem cells - COPD, Cystic Fibrosis | Phase 1 | Completed | University of Colorado, Denver | 15 | 2013-08-01 | 2018-02-08 |
| Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor - Transplantation, Stem Cell | Phase 1 | Completed | GlaxoSmithKline | 24 | 2012-11-02 | 2017-06-07 |
| Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia fludarabine, Idarubicin, cytarabine - Acute Myeloblastic Leukemia | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 55 | 2012-07-01 | 2017-04-25 |
| Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) Lenalidomide + Plerixafor (+ Rituximab) - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Completed | David Rizzieri, MD | 21 | 2012-01-01 | 2018-02-05 |
| Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Plerixafor - Failure of Bone Marrow Graft | Phase 1 / Phase 2 | Completed | Mitchell Horwitz, MD | 41 | 2011-12-01 | 2017-04-25 |
| A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent plerixafor, Placebo - Healthy Volunteer | Phase 1 | Completed | Genzyme, a Sanofi Company | 24 | 2011-09-01 | 2015-03-23 |
| Stem Cell Transplantation for Patients With Multiple Myeloma G-CSF, Plerixafor, Apheresis - Myeloma | Phase 1 | Completed | University of Chicago | 30 | 2011-07-12 | 2025-11-05 |
Showing 20 of 41. Sign in to see all of them.
Leukemia, Myeloid, Acute (12) · Leukemia (5) · Anemia, Sickle Cell (4) · Myelodysplastic Syndromes (4) · Fanconi Anemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Hodgkin Disease (2) · Neutropenia (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Agammaglobulinemia (1) · Brain Neoplasms (1)
Washington University School of Medicine (7) · Genzyme, a Sanofi Company (5) · Assistance Publique - Hôpitaux de Paris (2) · M.D. Anderson Cancer Center (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Alessandra Biffi (1) · CCTU- Cancer Theme (1) · Cardiff University (1) · Children's Hospital Medical Center, Cincinnati (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · David Rizzieri, MD (1) · Ensoma (1) · GlaxoSmithKline (1) · Hospital Infantil Universitario Niño Jesús, Madrid, Spain (1)
United States (33) · France (3) · Spain (3) · United Kingdom (3) · Canada (2) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1)
Alan K Burnett (1) · Alessandra Biffi, MD (1) · Amanda F. Cashen, M.D. (1) · Amrita Krishnan (1) · Ashok Srinivasan, MD (1) · David A Rizzieri, MD (1) · David C Dale, MD (1) · David H McDermott, M.D. (1) · Erica Esrick, MD (1) · Gail Roboz, MD (1) · Geoffrey L. Uy, M.D. (1) · Geoffrey L. Uy, MD (1)
PMID 21835955, PMID 21890643, PMID 22308295, PMID 24523241, PMID 24723677, PMID 27535663, PMID 27846612, PMID 28292947, PMID 28718760, PMID 29392425, PMID 29419425, PMID 29472357, PMID 29724902, PMID 31352850, PMID 31456261, PMID 31501599, PMID 31940591, PMID 32127657, PMID 33956057, PMID 34160085, PMID 34166998, PMID 34175041, PMID 34398557, PMID 34751952, PMID 36163427, PMID 39642902, PMID 40330596
2014 (3), P30CA124435 (1), R01HL081499 (1), R21CA143805 (1)